These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25190012)

  • 21. Biosimilars.
    Bagel J
    J Drugs Dermatol; 2014 Jul; 13(7):788-90. PubMed ID: 25007360
    [No Abstract]   [Full Text] [Related]  

  • 22. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations.
    Shaltout EL; Al-Ghobashy MA; Fathalla FA; Salem MY
    J Pharm Biomed Anal; 2014 Aug; 97():72-80. PubMed ID: 24816160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of biological samples by capillary electrophoresis with laser induced fluorescence detection.
    Szöko E; Tábi T
    J Pharm Biomed Anal; 2010 Dec; 53(5):1180-92. PubMed ID: 20719451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin.
    Reichel C; Thevis M
    Bioanalysis; 2013 Mar; 5(5):587-602. PubMed ID: 23425274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterizing biological products and assessing comparability following manufacturing changes.
    Chirino AJ; Mire-Sluis A
    Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 1st conference in Asia-Pacific on Recent Issues in Bioanalysis.
    Dumont I; Garofolo F
    Bioanalysis; 2011 Apr; 3(7):723-31. PubMed ID: 21452989
    [No Abstract]   [Full Text] [Related]  

  • 29. [What is exactly alike? High-performance analytics for development of biosimilars].
    Blüggel M
    Pharm Unserer Zeit; 2012 Nov; 41(6):468-73. PubMed ID: 23362550
    [No Abstract]   [Full Text] [Related]  

  • 30. Biotherapeutic bioanalysis: a multi-indication case study review.
    Myler HA; Given A; Kolz K; Mora JR; Hristopoulos G
    Bioanalysis; 2011 Mar; 3(6):623-43. PubMed ID: 21417732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solvent derived artifacts in natural products chemistry.
    Maltese F; van der Kooy F; Verpoorte R
    Nat Prod Commun; 2009 Mar; 4(3):447-54. PubMed ID: 19413130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation and approximation approaches for biosimilar index based on reproducibility probability.
    Yang LY; Lai CH
    J Biopharm Stat; 2014; 24(6):1298-311. PubMed ID: 25033191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioanalytical inspections: organizational changes and regulatory perspectives.
    Haidar SH; Scheibner KA
    Bioanalysis; 2016 May; 8(10):999-1002. PubMed ID: 27079934
    [No Abstract]   [Full Text] [Related]  

  • 34. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilars.
    Ross A; Richard K
    Conn Med; 2015 May; 79(5):295-9. PubMed ID: 26245019
    [No Abstract]   [Full Text] [Related]  

  • 37. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.
    Ghasriani H; Hodgson DJ; Brinson RG; McEwen I; Buhse LF; Kozlowski S; Marino JP; Aubin Y; Keire DA
    Nat Biotechnol; 2016 Feb; 34(2):139-41. PubMed ID: 26849514
    [No Abstract]   [Full Text] [Related]  

  • 39. Biosimilars: what's in a name?
    Silverman E
    BMJ; 2014 Jan; 348():g272. PubMed ID: 24443479
    [No Abstract]   [Full Text] [Related]  

  • 40. [Biosimilars: assessment of efficacy, safety and cost].
    Domínguez-Gil Hurlé A
    Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.